Literature DB >> 28464337

Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes.

Laura Sviklāne1,2, Evija Olmane2,3, Zane Dzērve1, Kārlis Kupčs2,3, Valdis Pīrāgs1,2, Jeļizaveta Sokolovska1,2.   

Abstract

BACKGROUND AND AIM: Little is known about the diagnostic value of hepatic steatosis index (HSI) and fatty liver index (FLI), as well as their link to metabolic syndrome in type 1 diabetes mellitus. We have screened the effectiveness of FLI and HSI in an observational pilot study of 40 patients with type 1 diabetes.
METHODS: FLI and HSI were calculated for 201 patients with type 1 diabetes. Forty patients with FLI/HSI values corresponding to different risk of liver steatosis were invited for liver magnetic resonance study. In-phase/opposed-phase technique of magnetic resonance was used. Accuracy of indices was assessed from the area under the receiver operating characteristic curve.
RESULTS: Twelve (30.0%) patients had liver steatosis. For FLI, sensitivity was 90%; specificity, 74%; positive likelihood ratio, 3.46; negative likelihood ratio, 0.14; positive predictive value, 0.64; and negative predictive value, 0.93. For HSI, sensitivity was 86%; specificity, 66%; positive likelihood ratio, 1.95; negative likelihood ratio, 0.21; positive predictive value, 0.50; and negative predictive value, 0.92. Area under the receiver operating characteristic curve for FLI was 0.86 (95% confidence interval [0.72; 0.99]); for HSI 0.75 [0.58; 0.91]. Liver fat correlated with liver enzymes, waist circumference, triglycerides, and C-reactive protein. FLI correlated with C-reactive protein, liver enzymes, and blood pressure. HSI correlated with waist circumference and C-reactive protein. FLI ≥ 60 and HSI ≥ 36 were significantly associated with metabolic syndrome and nephropathy.
CONCLUSIONS: The tested indices, especially FLI, can serve as surrogate markers for liver fat content and metabolic syndrome in type 1 diabetes.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  fatty liver index; hepatic steatosis index; metabolic syndrome; non-alcoholic fatty liver disease; type 1 diabetes mellitus

Mesh:

Substances:

Year:  2018        PMID: 28464337     DOI: 10.1111/jgh.13814

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  31 in total

1.  Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes.

Authors:  Phuc Le; Alexander Chaitoff; Michael B Rothberg; Naim Alkhouri; Arthur McCullough
Journal:  J Gen Intern Med       Date:  2019-11       Impact factor: 5.128

Review 2.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

3.  A long-term anti-inflammation markedly alleviated high-fat diet-induced obesity by repeated administrations of overexpressing IL10 human umbilical cord-derived mesenchymal stromal cells.

Authors:  Liudi Wang; Tianyun Gao; Yu Li; Yuanyuan Xie; Sheng Zeng; Chenxu Tai; Yirui Feng; Pingping Shen; Bin Wang
Journal:  Stem Cell Res Ther       Date:  2022-06-17       Impact factor: 8.079

4.  Comparison of the Modified TyG Indices and Other Parameters to Predict Non-Alcoholic Fatty Liver Disease in Youth.

Authors:  Kyungchul Song; Hae Won Lee; Han Saem Choi; Goeun Park; Hye Sun Lee; Su Jin Kim; Myeongseob Lee; Junghwan Suh; Ahreum Kwon; Ho-Seong Kim; Hyun Wook Chae
Journal:  Biology (Basel)       Date:  2022-04-29

5.  Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults.

Authors:  Richard K Sterling; Wendy C King; Mandana Khalili; David E Kleiner; Amanda S Hinerman; Mark Sulkowski; Raymond T Chung; Mamta K Jain; M Auricio Lisker-Melman; David K Wong; Marc G Ghany
Journal:  Dig Dis Sci       Date:  2021-02-08       Impact factor: 3.487

6.  Associations between fatty liver index and asymptomatic intracranial vertebrobasilar stenosis in Chinese population.

Authors:  Jing Qiu; Zhiwei Zhou; Jie Wang; Yiying Wang; Chunxing Liu; Xingxiang Liu; Yunfang Xu; Lugang Yu; Hui Zhou; Jie Lin; Zhirong Guo; Chen Dong
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

7.  Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes.

Authors:  Ruchi Jain; Türküler Özgümüş; Troels Mygind Jensen; Elsa du Plessis; Magdalena Keindl; Cathrine Laustrup Møller; Henrik Falhammar; Thomas Nyström; Sergiu-Bogdan Catrina; Gun Jörneskog; Leon Eyrich Jessen; Carol Forsblom; Jani K Haukka; Per-Henrik Groop; Peter Rossing; Leif Groop; Mats Eliasson; Björn Eliasson; Kerstin Brismar; Mahmoud Al-Majdoub; Peter M Nilsson; Marja-Riitta Taskinen; Ele Ferrannini; Peter Spégel; Tore Julsrud Berg; Valeriya Lyssenko
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

8.  Effects of different exercise modalities on novel hepatic steatosis indices in overweight women with type 2 diabetes.

Authors:  Ebrahim Banitalebi; Mohammad Faramarzi; Samira Nasiri; Majid Mardaniyan; Vahid Rabiee
Journal:  Clin Mol Hepatol       Date:  2019-05-30

9.  Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study.

Authors:  Valentina Guarnotta; Mariagrazia Irene Mineo; Stefano Radellini; Giuseppe Pizzolanti; Carla Giordano
Journal:  Ther Adv Endocrinol Metab       Date:  2019-08-28       Impact factor: 3.565

10.  Hepatic Steatosis Index and Chronic Kidney Disease among Middle-Aged Individuals: A Large-Scale Study in Japan.

Authors:  Hirotaka Ochiai; Takako Shirasawa; Takahiko Yoshimoto; Satsue Nagahama; Ken Sakamoto; Minami Azuma; Akatsuki Kokaze
Journal:  Dis Markers       Date:  2021-06-09       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.